In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...

Treatment for arthritis is mainly focused on symptom management and slowing the progression of the disease, says Dr Vishal ...

Arthritis, often thought to be an ailment of the elderly, is an autoimmune disease prevalent across all ages, particularly in ...

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

The following is a summary of “Opioid Use and Healthcare Utilization in Adults With Psoriatic Arthritis and Ankylosing ...

The following is a summary of “Difficult-to-Treat Concept in Psoriatic Arthritis: Analysis of 2 Potential Definitions in a ...